1月26日，普瑞眼科涨0.66%，成交额6666.17万元。两融数据显示，当日普瑞眼科获融资买入额606.50 万元，融资偿还789.30万元，融资净买入-182.80万元。截至1月26日，普瑞眼科融资融券余额合计 7037.43万元。 融资方面，普瑞眼科当日融资买入606.50万元。当前融资余额7033.90万元，占流通市值的1.33%，融资 余额低于近一年10%分位水平，处于低位。 融券方面，普瑞眼科1月26日融券偿还1900.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量1000.00股，融券余额3.53万元，低于近一年10%分位水平，处于低位。 截至9月30日，普瑞眼科股东户数1.04万，较上期减少1.98%；人均流通股13608股，较上期增加 104.71%。2025年1月-9月，普瑞眼科实现营业收入22.01亿元，同比增长2.99%；归母净利润1634.91万 元，同比增长3.21%。 分红方面，普瑞眼科A股上市后累计派现7450.74万元。 机构持仓方面，截止2025年9月30日，普瑞眼科十大流通股东中，融通健康产业灵活配置混合A/B （000727）位居第八大流通 ...

Group 1 - Core viewpoint: Puri Eye Hospital has seen a continuous increase in stock price, with a 5-day cumulative increase of 5.84% as of January 14, reaching a price of 34.26 yuan per share and a total market capitalization of 5.126 billion yuan [1] - Company overview: Puri Eye Hospital Group Co., Ltd. was established on March 23, 2006, and went public on July 5, 2022. The company provides comprehensive medical services for eye diseases, including diagnosis, treatment, healthcare, and optical services [1] - Revenue composition: The main business revenue is derived from refractive projects (49.36%), cataract projects (19.77%), comprehensive eye disease projects (16.65%), vision projects (13.03%), and other services (1.18%) [1] Group 2 - Shareholder information: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund (000727) is among the top ten circulating shareholders of Puri Eye Hospital, having reduced its holdings by 192,500 shares in the third quarter, now holding 2.4 million shares, which is 1.69% of the circulating shares [2] - Fund performance: The Rongtong Health Industry Flexible Allocation Mixed A/B Fund has achieved a year-to-date return of 9.61% and a one-year return of 26.99%, ranking 782 out of 8,838 and 4,859 out of 8,089 respectively [2] - Fund manager details: The fund manager, Wan Minyuan, has a tenure of 9 years and 144 days, with a total fund asset size of 5.957 billion yuan and a best return of 149.74% during his tenure [2]

Core Viewpoint - On November 7, 2023, Puri Eye Hospital's stock decreased by 0.22%, with a trading volume of 27.86 million yuan, indicating a relatively stable market performance despite minor fluctuations [1] Financing Summary - On November 7, Puri Eye Hospital had a financing buy-in amount of 3.47 million yuan and a financing repayment of 3.18 million yuan, resulting in a net financing buy-in of 0.28 million yuan [1] - The total financing and securities balance as of November 7 was 72.47 million yuan, with the financing balance at 71.80 million yuan, accounting for 1.30% of the circulating market value, which is below the 10th percentile level over the past year, indicating a low financing level [1] - The securities lending data showed a repayment of 100 shares with no shares sold, and a remaining securities lending balance of 67.53 million yuan, which is above the 60th percentile level over the past year, indicating a relatively high level of securities lending [1] Business Performance - As of September 30, 2023, Puri Eye Hospital reported a total revenue of 2.20 billion yuan for the first nine months of 2023, reflecting a year-on-year growth of 2.99% [2] - The net profit attributable to the parent company for the same period was 16.35 million yuan, showing a year-on-year increase of 3.21% [2] - The company has distributed a total of 74.51 million yuan in dividends since its A-share listing [3] Shareholder Information - As of September 30, 2023, the number of shareholders for Puri Eye Hospital was 10,400, a decrease of 1.98% from the previous period, while the average circulating shares per person increased by 104.71% to 13,608 shares [2] - Among the top ten circulating shareholders, the Rongtong Health Industry Flexible Allocation Mixed A/B Fund held 2.40 million shares, a decrease of 192,500 shares from the previous period, while the Yuanxin Yongfeng Medical Health A Fund entered the top ten with 2.02 million shares [3]

Core Insights - On October 10, 2023, Puri Eye Hospital's stock rose by 0.87%, with a trading volume of 50.26 million yuan [1] - The company reported a financing buy-in of 3.29 million yuan and a net financing buy of 135,200 yuan on the same day [1] - As of October 10, the total margin balance for Puri Eye Hospital was 70.78 million yuan, indicating a low financing balance compared to the past year [1] Financing and Margin Data - On October 10, the financing buy-in was 3.29 million yuan, while the financing repayment was 3.15 million yuan, resulting in a net buy of 135,200 yuan [1] - The current financing balance stands at 70.13 million yuan, which is 1.27% of the circulating market value, below the 10% percentile level over the past year [1] - The margin trading data shows that 200 shares were repaid, and 1,700 shares were sold short, with a short selling amount of 63,000 yuan [1] Company Overview - Puri Eye Hospital Group Co., Ltd. was established on March 23, 2006, and went public on July 5, 2022 [1] - The company provides comprehensive eye care services, including diagnosis, treatment, and optical services [1] - The revenue composition includes refractive projects (49.36%), cataract projects (19.77%), comprehensive eye disease projects (16.65%), and optical projects (13.03%) [1] Shareholder and Financial Performance - As of June 30, 2023, the number of shareholders increased by 6.24% to 10,600, while the average circulating shares per person decreased by 5.87% to 6,647 shares [2] - For the first half of 2023, Puri Eye Hospital achieved a revenue of 1.46 billion yuan, a year-on-year increase of 2.74%, but the net profit attributable to shareholders decreased by 66.12% to 14.67 million yuan [2] - Cumulatively, the company has distributed 74.51 million yuan in dividends since its A-share listing [3]

Core Viewpoint - The financial performance of Purui Eye Hospital Group shows mixed results, with a slight increase in revenue but a significant decrease in net profit, indicating potential challenges in profitability despite stable revenue growth [2][3]. Group 1: Financial Performance - As of June 30, 2025, Purui Eye Hospital achieved a revenue of 1.459 billion yuan, representing a year-on-year growth of 2.74% [2]. - The net profit attributable to shareholders for the same period was 14.67 million yuan, reflecting a substantial decline of 66.12% compared to the previous year [2]. - Cumulative cash dividends distributed since the company's A-share listing amount to 74.51 million yuan [3]. Group 2: Shareholder and Market Activity - As of August 28, 2023, the total number of shareholders for Purui Eye Hospital reached 10,600, an increase of 6.24% from the previous period [2]. - The average number of circulating shares per shareholder is 6,647, which is a decrease of 5.87% from the previous period [2]. - On August 28, 2023, the financing balance for Purui Eye Hospital was 94.61 million yuan, accounting for 1.47% of its market capitalization, indicating a low financing level compared to the past year [1]. Group 3: Institutional Holdings - As of June 30, 2025, the third-largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.5925 million shares, an increase of 692,400 shares from the previous period [3]. - Yuanxin Yongfeng Ju You A is a new entrant among the top ten circulating shareholders, holding 1.7668 million shares [3]. - The tenth-largest circulating shareholder, ICBC Medical Care Stock, reduced its holdings by 90,000 shares compared to the previous period [3].